Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A

As of June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A carries a market capitalization of 28.66B, placing it among publicly traded companies globally. Its enterprise value stands at 26.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A has 770.09M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A maintains a current ratio of 1.38, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A recorded 111.48M in income tax expense.

As of the close on October 23, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A's stock has declined approximately 4.80% over the past 52 weeks. The 50-day moving average sits at 36.28, while the 200-day moving average is 40.24.

As of June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A holds 2.45B in cash and equivalents against 88.89M in total debt, resulting in a net debt position of -2.37B. Total book value stands at 5.94B, with working capital of 1.72B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A paid dividends of 2.44 per share.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A's most recent stock split took place on July 5, 2010 with a 1:2 split ratio.